Leverage remains minimal, with total debt flat near $2.7B and debt-to-equity of 0.08 in 2026Q3, while the current ratio compressed from 5.44 to 3.35, still indicating a comfortable liquidity cushion.
Regeneron Pharmaceuticals, Inc. (REGN) balance sheet — 30-year assets, liabilities & shareholders' equity history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 | Dec'04 | Dec'03 | Dec'02 | Dec'01 | Dec'00 | Dec'99 | Dec'98 | Dec'97 | Dec'96 |
|---|
| Total Current Assets | 20.8B | 18.02B | 18.66B | 19.48B | 15.88B | 14.01B | 9.78B | 7.69B | 7.96B | 5.6B | 3.91B | 3.38B | 2.51B | 2.25B | 1.62B | 913.59M | 720.05M | 425.51M | 521.44M | 797.83M | 469.98M | 341.39M | 343.95M | 320.21M | 276.95M | 394.19M | 134.14M | 73M | 92.9M | 99.6M | 85M |
| Cash & Short-Term Investments | 9.3B | 8.61B | 9.01B | 10.84B | 7.74B | 5.69B | 3.59B | 3.21B | 2.81B | 1.41B | 1.04B | 1.05B | 900.48M | 693.98M | 308.1M | 526.94M | 249.37M | 341.33M | 474.75M | 766.46M | 459.28M | 298.55M | 295.98M | 293.77M | 264.27M | 385.08M | 117.61M | 66.2M | 19.8M | 28.9M | 34.5M |
| Cash Only | 3.66B | 3.12B | 2.49B | 2.73B | 3.11B | 2.89B | 2.19B | 1.62B | 1.47B | 812.73M | 535.2M | 809.1M | 648.72M | 535.61M | 230.28M | 483.61M | 112.57M | 207.07M | 247.8M | 498.93M | 237.88M | 184.51M | 101.23M | 118.28M | 80.08M | 247.39M | 30.98M | 23.7M | 19.8M | 28.9M | 34.5M |
| Short-Term Investments | 5.64B | 5.49B | 6.52B | 8.11B | 4.64B | 2.81B | 1.39B | 1.6B | 1.34B | 596.85M | 503.48M | 236.12M | 251.76M | 158.38M | 77.82M | 43.33M | 136.8M | 134.25M | 226.95M | 267.53M | 221.4M | 114.04M | 194.75M | 175.49M | 184.19M | 137.69M | 86.63M | 42.5M | 0 | 0 | 0 |
| Accounts Receivable | 7.58B | 5.74B | 6.21B | 5.67B | 5.33B | 6.04B | 4.11B | 2.79B | 2.24B | 1.97B | 1.61B | 1.47B | 976.37M | 954.97M | 693.12M | 103.03M | 81.92M | 65.57M | 35.21M | 18.32M | 7.49M | 36.52M | 43.1M | 15.53M | 4.02M | 2.98M | 13.84M | 600K | 5.7M | 6.6M | 4.3M |
| Days Sales Outstanding | 138.34 | 146.1 | 159.65 | 157.7 | 159.78 | 137.09 | 176.75 | 155.05 | 122.01 | 122.72 | 121.03 | 130.55 | 126.39 | 165.61 | 183.53 | 84.36 | 65.13 | 63.1 | 53.9 | 53.48 | 43.11 | 201.38 | 90.41 | 98.58 | 66.68 | 49.42 | 85.19 | 6.35 | 54.46 | 72.78 | 65.12 |
| Inventory | 2.89B | 3.2B | 3.09B | 2.58B | 2.4B | 1.95B | 1.92B | 1.42B | 1.15B | 726.14M | 399.36M | 238.58M | 128.86M | 70.35M | 28.64M | 13.56M | -15.14M | 0 | 0 | 0 | 0 | 2.9M | 3.23M | 9.01M | 6.83M | 3.97M | 1.92M | 4.6M | 0 | 0 | 0 |
| Days Inventory Outstanding | 466.22 | 556.14 | 571.87 | 419.64 | 514.13 | 261.49 | 515.98 | 529.69 | 721.6 | 488.53 | 360.41 | 186.22 | 182.51 | 130.64 | 86.11 | 140.18 | - | - | - | - | - | 42.3 | 7.79 | 492.39 | 384.59 | 222.79 | 44.9 | 466.39 | - | - | - |
| Other Current Assets | 0 | 474.8M | 349.2M | 386.6M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 44.68M | 148.13M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.6M | 67.4M | 64.1M | 46.2M |
| Total Non-Current Assets | 23.61B | 22.54B | 19.1B | 13.6B | 13.33B | 11.42B | 7.38B | 7.12B | 5.29B | 4.43B | 3.79B | 2.69B | 1.75B | 1.15B | 874.48M | 657.81M | 731.81M | 315.69M | 202.78M | 138.43M | 115.11M | 82.11M | 129.15M | 159.35M | 114.63M | 101.21M | 74.13M | 64M | 64M | 68.8M | 52.6M |
| Property, Plant & Equipment | 5.73B | 5.12B | 4.6B | 4.15B | 3.76B | 3.48B | 3.22B | 2.89B | 2.58B | 2.36B | 2.08B | 1.59B | 974.31M | 526.98M | 379.94M | 367.95M | 347.45M | 259.68M | 87.85M | 58.3M | 49.35M | 60.53M | 71.24M | 80.72M | 76.83M | 39.45M | 36.93M | 36.3M | 33M | 32.7M | 34.3M |
| Fixed Asset Turnover | 3.13x | 2.80x | 3.09x | 3.16x | 3.23x | 4.62x | 2.64x | 2.27x | 2.61x | 2.49x | 2.33x | 2.57x | 2.89x | 3.99x | 3.63x | 1.21x | 1.32x | 1.46x | 2.71x | 2.14x | 1.29x | 1.09x | 2.44x | 0.71x | 0.29x | 0.56x | 1.60x | 0.95x | 1.16x | 1.01x | 0.70x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 1.32B | 1.26B | 1.15B | 1.04B | 915.5M | 6.7M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 39.43B | 10.26B | 8.9B | 5.4B | 6.59B | 6.84B | 3.14B | 3.26B | 1.75B | 1.49B | 864.26M | 632.16M | 460.15M | 389.89M | 271.23M | 275.89M | 370.05M | 47.08M | 51.06M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 2.47B | 1.82B | 1.14B | 444.1M | 336.4M | 216.1M | 168.1M | 144.7M | 127.4M | 77.9M | 20.29M | 5.81M | 3.03M | 5.33M | 31.29M | 13.96M | 14.31M | 8.94M | 9.68M | 1.9M | 65.75M | 21.57M | 57.91M | 78.63M | 37.8M | 61.76M | 37.2M | 27.7M | 31M | 36.1M | 18.3M |
| Total Assets | 44.41B | 40.56B | 37.76B | 33.08B | 29.21B | 25.43B | 17.16B | 14.81B | 11.73B | 8.76B | 6.97B | 5.61B | 3.87B | 2.95B | 2.08B | 1.32B | 1.09B | 741.2M | 670.04M | 936.26M | 585.09M | 423.5M | 473.11M | 479.56M | 391.57M | 495.4M | 208.27M | 137M | 156.9M | 168.4M | 137.6M |
| Asset Turnover | 0.40x | 0.35x | 0.38x | 0.40x | 0.42x | 0.63x | 0.50x | 0.44x | 0.57x | 0.67x | 0.70x | 0.73x | 0.73x | 0.71x | 0.66x | 0.34x | 0.42x | 0.51x | 0.36x | 0.13x | 0.11x | 0.16x | 0.37x | 0.12x | 0.06x | 0.04x | 0.28x | 0.25x | 0.24x | 0.20x | 0.18x |
| Asset Growth % | 36% | 7.41% | 14.14% | 13.23% | 14.86% | 48.19% | 15.93% | 26.17% | 33.89% | 25.68% | 24.32% | 44.87% | 31.2% | 41.84% | 57.19% | 21.49% | 46.98% | 10.62% | -28.43% | 60.02% | 38.16% | -10.49% | -1.34% | 22.47% | -20.96% | 137.86% | 52.02% | -12.68% | -6.83% | 22.38% | 46.7% |
| Total Current Liabilities | 6.2B | 4.37B | 3.94B | 3.42B | 3.14B | 3.93B | 2.7B | 2.1B | 1.44B | 1.14B | 1.24B | 811.16M | 654.66M | 298.83M | 163.55M | 148.27M | 109.06M | 93.58M | 83.67M | 283.66M | 45.01M | 40.36M | 34.14M | 72.92M | 40.12M | 22.02M | 13.79M | 13.3M | 9.4M | 10.7M | 12M |
| Accounts Payable | 1.14B | 939M | 789.5M | 606.6M | 589.2M | 564M | 475.5M | 418.1M | 218.2M | 178.2M | 134.98M | 140.96M | 99.51M | 61.94M | 38.93M | 27.74M | 15.59M | 18.64M | 6.27M | 8.13M | 4.35M | 4.2M | 4.41M | 18.93M | 30.31M | 14.83M | 9.45M | 6.6M | 5.6M | 4.7M | 4.4M |
| Days Payables Outstanding | 161.91 | 163.15 | 146.24 | 98.65 | 126.12 | 75.58 | 128.01 | 156.46 | 136.77 | 119.89 | 121.82 | 110.03 | 140.94 | 115.01 | 117.06 | 286.8 | 261.25 | 426.97 | 187.37 | - | 69.81 | 61.21 | 10.63 | 1.04K | 1.71K | 831.61 | 221.49 | 669.17 | 408.8 | 659.81 | 1.46K |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 200M | 0 | 0 | 0 | 13.82M | 150K | 426K | 612K | 1.4M | 1.1M | 1.8M | 3.6M |
| Deferred Revenue (Current) | 2.16B | 553M | 627.7M | 458.9M | 477.9M | 442M | 577.7M | 591.7M | 452.5M | 320.14M | 231.66M | 153.49M | 74.03M | 47M | 50.83M | 300.25M | 54.72M | 44.54M | 209.93M | 44.43M | 23.54M | 17.02M | 15.27M | 40.17M | 9.66M | 6.77M | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 85M | 0 | 0 | 1.18M | 13.56M | 97.15M | 0 | 0 | 0 | 12.03M | 0 | 0 | 0 | 0 | 2.29M | 0 | 0 | 0 | 0 | 0 | 5.3M | 2.7M | 4.2M | 4M |
| Current Ratio | 3.35x | 4.13x | 4.73x | 5.69x | 5.06x | 3.56x | 3.63x | 3.67x | 5.52x | 4.93x | 3.15x | 4.17x | 3.83x | 7.54x | 9.91x | 6.16x | 6.60x | 4.55x | 6.23x | 2.81x | 10.44x | 8.46x | 10.08x | 4.39x | 6.90x | 17.90x | 9.73x | 5.49x | 9.88x | 9.31x | 7.08x |
| Quick Ratio | 2.89x | 3.39x | 3.95x | 4.94x | 4.29x | 3.07x | 2.91x | 2.99x | 4.72x | 4.29x | 2.83x | 3.88x | 3.63x | 7.30x | 9.73x | 6.07x | 6.74x | 4.55x | 6.23x | 2.81x | 10.44x | 8.39x | 9.98x | 4.27x | 6.73x | 17.72x | 9.59x | 5.14x | 9.88x | 9.31x | 7.08x |
| Cash Conversion Cycle | 442.66 | 539.09 | 585.28 | 478.69 | 547.79 | 323 | 564.71 | 528.28 | 706.83 | 491.36 | 359.62 | 206.75 | 167.97 | 181.24 | 152.57 | -62.27 | - | - | - | - | - | 182.46 | 87.56 | -444.16 | -1.26K | -559.4 | -91.4 | -196.43 | - | - | - |
| Total Non-Current Liabilities | 4.7B | 4.93B | 4.46B | 3.68B | 3.41B | 2.73B | 3.44B | 1.62B | 1.53B | 1.48B | 1.28B | 1.14B | 632.76M | 700.1M | 671.55M | 689.58M | 452.56M | 250.87M | 219.03M | 192.33M | 323.45M | 269.14M | 256.43M | 268.99M | 205.47M | 207.02M | 12.36M | 14.2M | 16.3M | 18.8M | 18.7M |
| Long-Term Debt | 1.99B | 1.99B | 1.98B | 1.98B | 1.98B | 1.98B | 1.98B | 0 | 0 | 0 | 0 | 0 | 146.77M | 320.31M | 296.52M | 275.02M | 0 | 0 | 5.09M | 0 | 200M | 200M | 200M | 200M | 200M | 200M | 1.47M | 2.7M | 3.1M | 3.8M | 5.1M |
| Capital Lease Obligations | 720M | 720M | 720M | 720M | 720M | 0 | 717.2M | 713.9M | 708.5M | 703.5M | 351.57M | 362.92M | 310.94M | 184.26M | 159.44M | 159.51M | 162.18M | 109.02M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 150K | 603K | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 2.5B | 2.02B | 1.57B | 854.1M | 638M | 680.2M | 687.1M | 799.7M | 546.6M | 949.29M | 100.39M | 115.53M | 217.13M | 11.33M | 7.26M | -247.6M | 52.57M | 3.96M | 0 | 0 | 0 | 0 | 0 | 159K | 0 | 0 | 10.29M | 11.5M | 13.2M | 15M | 13.6M |
| Total Liabilities | 10.91B | 9.3B | 8.41B | 7.11B | 6.55B | 6.67B | 6.14B | 3.72B | 2.98B | 2.62B | 2.52B | 1.95B | 1.33B | 998.94M | 835.11M | 837.85M | 561.62M | 344.44M | 251.19M | 475.99M | 368.47M | 309.5M | 290.56M | 341.91M | 245.59M | 229.04M | 26.14M | 27.5M | 25.7M | 29.5M | 30.7M |
| Total Debt | 2.71B | 2.71B | 2.7B | 2.7B | 2.7B | 2.7B | 2.7B | 713.9M | 708.5M | 703.45M | 481.13M | 375.51M | 459.06M | 505.51M | 457.33M | 435.53M | 160.03M | 109.02M | 5.09M | 202.29M | 200M | 200M | 200M | 213.82M | 200.15M | 200.58M | 2.68M | 4.1M | 4.2M | 5.6M | 8.7M |
| Net Debt | -952.1M | -412.2M | 216.2M | -27.1M | -404.5M | -185.9M | 502M | -903.9M | -759.2M | -109.28M | -54.08M | -433.59M | -189.66M | -30.1M | 227.05M | -48.08M | 47.46M | -98.05M | -242.7M | -296.63M | -37.88M | 15.49M | 98.77M | 95.53M | 120.07M | -46.82M | -28.3M | -19.6M | -15.6M | -23.3M | -25.8M |
| Debt / Equity | 0.08x | 0.09x | 0.09x | 0.10x | 0.12x | 0.14x | 0.24x | 0.06x | 0.08x | 0.11x | 0.11x | 0.10x | 0.18x | 0.26x | 0.37x | 0.90x | 0.30x | 0.27x | 0.01x | 0.44x | 0.92x | 1.75x | 1.10x | 1.55x | 1.37x | 0.75x | 0.01x | 0.04x | 0.03x | 0.04x | 0.08x |
| Debt / EBITDA | 0.49x | 0.66x | 0.60x | 0.57x | 0.47x | 0.29x | 0.71x | 0.29x | 0.26x | 0.32x | 0.34x | 0.28x | 0.52x | 0.64x | 0.92x | - | - | - | - | - | - | - | 9.52x | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | -0.17x | -0.10x | 0.05x | -0.01x | -0.07x | -0.02x | 0.13x | -0.37x | -0.28x | -0.05x | -0.04x | -0.33x | -0.22x | -0.04x | 0.46x | - | - | - | - | - | - | - | 4.70x | - | - | - | - | - | - | - | - |
| Interest Coverage | 122.77x | 120.42x | 87.59x | 58.52x | 82.80x | 163.75x | 67.97x | 81.43x | 91.55x | 83.75x | 185.82x | 87.03x | 21.76x | 16.36x | 10.15x | -9.47x | -10.46x | -29.79x | -9.37x | -7.77x | - | - | - | - | - | - | -5.52x | - | - | -4.03x | -1.21x |
| Total Equity | 33.5B | 31.26B | 29.35B | 25.97B | 22.66B | 18.77B | 11.03B | 11.09B | 8.76B | 6.14B | 4.45B | 3.65B | 2.54B | 1.95B | 1.25B | 485.73M | 527.82M | 396.76M | 418.85M | 460.27M | 216.62M | 114M | 182.54M | 137.64M | 145.98M | 266.36M | 182.13M | 109.5M | 131.2M | 138.9M | 106.9M |
| Equity Growth % | 27.54% | 6.48% | 13.02% | 14.6% | 20.75% | 70.23% | -0.58% | 26.63% | 42.53% | 38.09% | 21.74% | 43.76% | 30.24% | 56.74% | 156.39% | -7.97% | 33.03% | -5.27% | -9% | 112.47% | 90.02% | -37.55% | 32.62% | -5.71% | -45.19% | 46.24% | 66.33% | -16.54% | -5.54% | 29.93% | 57.44% |
| Book Value per Share | 317.22 | 287.82 | 255.03 | 228.44 | 199.68 | 167.28 | 95.79 | 96.77 | 76.28 | 53.01 | 38.26 | 31.72 | 22.41 | 17.54 | 10.79 | 5.36 | 6.36 | 4.97 | 5.31 | 6.94 | 3.74 | 2.04 | 3.25 | 2.73 | 3.32 | 6.33 | 5.18 | 3.48 | 4.23 | 4.79 | 4.37 |
| Total Shareholders' Equity | 33.5B | 31.26B | 29.35B | 25.97B | 22.66B | 18.77B | 11.03B | 11.09B | 8.76B | 6.14B | 4.45B | 3.65B | 2.54B | 1.95B | 1.25B | 485.73M | 527.82M | 396.76M | 418.85M | 460.27M | 216.62M | 114M | 182.54M | 137.64M | 145.98M | 266.36M | 182.13M | 109.5M | 131.2M | 138.9M | 106.9M |
| Common Stock | 100K | 100K | 100K | 100K | 100K | 100K | 100K | 100K | 100K | 112K | 110K | 108K | 104K | 99K | 97K | 93K | 89K | 81K | 80K | 79K | 65K | 56K | 56K | 55K | 44K | 44K | 37K | 0 | 0 | 0 | 0 |
| Retained Earnings | 39.47B | 35.8B | 31.67B | 27.26B | 23.31B | 18.97B | 10.89B | 7.38B | 5.25B | 2.95B | 1.75B | 852.7M | 255.38M | -92.69M | -517.05M | -1.27B | -1.05B | -941.1M | -875.93M | -793.22M | -687.62M | -585.28M | -489.83M | -531.53M | -424.07M | -299.7M | -223.52M | -200.3M | -177.2M | -168.6M | -157M |
| Treasury Stock | -20.95B | -18.61B | -15.17B | -12.56B | -10.35B | -8.26B | -6.61B | -739.9M | -396.4M | -316.24M | -316.24M | -306.07M | -169.53M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -197.5M | 77.5M | -7.9M | -80.9M | -238.8M | -26.2M | 29.3M | 21.1M | -12.3M | 640K | -12.84M | 8.57M | 52.25M | -1.19M | -1.17M | -1.86M | -2.49M | 1.04M | -114K | 170K | -231K | -785K | -3.07M | -4M | -3.17M | -1.61M | -780K | -500K | -26.6M | -23.6M | -5.9M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying REGN stock.
As of 2025, Regeneron Pharmaceuticals, Inc. (REGN) had total assets of $40.56B including $18.02B in current assets.
Regeneron Pharmaceuticals, Inc. (REGN) carries total debt of $2.71B, offset by $8.61B in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Regeneron Pharmaceuticals, Inc. (REGN) has total shareholders' equity (book value) of $31.26B ($287.82 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Regeneron Pharmaceuticals, Inc. (REGN) reported a current ratio of 4.13x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.
Key Metrics
Top Statement Risk
Revenue lumpiness and buyback-driven cash use
Metrics are mathematically derived from official filings.
Equity Base Compounding Through Retained Earnings
Based on REGN's reported quarterly balance sheets, total equity rose from $28.2B in 2024Q2 to $33.5B in 2026Q3, with retained earnings climbing to $39.5B, a pattern consistent with sustained profit retention over the period.
The steady rise in retained earnings, which grew by roughly $10B across the ten quarters, suggests the company has been converting operating profits into balance sheet strength rather than distributing them. Total assets expanded from $36.1B to $44.4B over the same span, indicating the equity build is translating into a larger asset base rather than being absorbed by liabilities. Investors should monitor whether this retention pace persists given the quarterly volatility in earnings noted in the prior income statement findings.
Minimal Leverage Despite Stable Debt Load
According to reported figures, REGN's total debt held flat near $2.7B across all ten quarters, while the debt-to-equity ratio declined from roughly 0.10 to 0.08, reflecting equity growth outpacing a fixed debt base.
A flat debt balance alongside rising equity means leverage has been diluting passively rather than being actively managed, which suggests the company has had no need to refinance or add borrowings. The very low D/E ratio implies limited financial risk from interest obligations or refinancing windows based on the supplied data. The absence of debt growth does not by itself confirm conservative policy, and the data does not disclose maturity schedules, so refinancing risk cannot be fully assessed from these figures.
Current Ratio Compression Toward Healthy Levels
As reported in financial statements, REGN's current ratio fell from 5.44 in 2024Q2 to 3.35 in 2026Q3, while cash held in a band of roughly $2.0B to $3.7B, leaving a still-comfortable liquidity cushion.
The decline in current ratio reflects growth in current liabilities, which may include deferred revenue and operating obligations, rather than any erosion of current assets. Cash balances remain well above the company's debt, which supports short-term resilience even as the ratio normalizes. The data does not include operating expense detail, so cash runway relative to burn cannot be calculated, and no conclusion about shock absorption beyond the reported ratios is warranted.
Asset-Light Profile With Modest Fixed Capital
Based on REGN's reported figures, net PP&E grew steadily from $4.3B to $5.7B while goodwill remained near $1.1B to $1.4B, suggesting a balance sheet anchored by physical manufacturing capacity rather than acquisition-driven intangibles.
Rising PP&E alongside stable goodwill indicates the company is investing in internal production and research infrastructure instead of growing through acquisitions. This lowers the risk of a large goodwill impairment charge that could distort reported equity. The asset mix is consistent with a biotechnology business whose value rests largely on proprietary products and pipeline rather than on tangible asset intensity.
Deferred Revenue Volatility Limits Forward Read
According to reported quarterly data, deferred revenue swung between $220.4M in 2026Q2 and $970.0M in 2026Q3, indicating that forward-booked revenue is lumpy and offers limited visibility into near-term top-line trajectory.
Deferred revenue appears to be driven by milestone timing and collaboration arrangements rather than recurring subscriptions, which explains the wide quarterly variance. This pattern suggests that a single period's balance is a weak predictor of the next quarter's revenue. Investors should treat the deferred revenue line as a signal requiring context from pipeline and partnership disclosures rather than as a reliable backlog indicator.
Headline Strength Masks Lumpy Underlying Cash Quality
Based on reported figures, the strong equity and low leverage profile may overstate cash resilience, since free cash flow margins swung from 4.0% to 37.8% across quarters and share repurchases often absorbed most of that generation.
A strong balance sheet built on retained earnings can coexist with weak cash conversion when earnings include non-operating items, as the income statement findings already suggest. If buybacks continue at the reported pace, the equity base may grow more slowly than headline retained earnings imply. This warrants further investigation into the quality of reported earnings before treating the balance sheet as a durable buffer.